# Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases

> **NCT04967417** · PHASE2 · COMPLETED · sponsor: **Samsung Medical Center** · enrollment: 13 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed, Carboplatin, Pembrolizumab
- **DRUG:** Paclitaxel, Carboplatin, Pembrolizumab

## Key facts

- **NCT ID:** NCT04967417
- **Lead sponsor:** Samsung Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-05-26
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-02
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2025-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04967417

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04967417, "Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT04967417. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*